- This 4.7-year, prospective study of 19,114 older adults evaluated the association between daily aspirin therapy and mortality. Compared with patients randomized to placebo, patients receiving 100 mg of enteric-coated aspirin had a higher mortality rate (12.7 vs 11.1 events per 1000 person-years). The mortality risk was associated with a higher rate of cancer-related deaths in the aspirin group compared with the placebo group (3.1% vs 2.3%, respectively).
- These results are unexpected and inconsistent with those of previous studies, and the authors suggest that clinicians should interpret them with caution.
- Data from The Health Improvement Network in the UK were analyzed to evaluate the benefit of aspirin for the primary prevention of cardiovascular events among patients with type 2 diabetes mellitus (T2D) and heart failure (HF). After a mean follow-up of 5 years, the use of aspirin was associated with a significant reduction in the risk of the primary composite outcome of all‐cause mortality and hospitalization for HF and a reduction in all‐cause mortality alone. In addition, the use of aspirin was associated with an increased risk of nonfatal myocardial infarction and nonfatal stroke. Aspirin use did not increase the risk of major bleeding, and there was no additional benefit seen with a dose >75 mg.
- The use of aspirin for the primary prevention of cardiovascular events among patients with T2D and HF is associated with a reduction in all‐cause mortality.
Aucun commentaire:
Enregistrer un commentaire